Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition

Clin Exp Metastasis. 2020 Apr;37(2):283-292. doi: 10.1007/s10585-020-10021-7. Epub 2020 Feb 4.

Abstract

We explored the role of the transcription factor, NF-κB, and its upstream kinase IKKβ in regulation of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma (HNSCC). We showed that cisplatin-resistant HNSCC cells have a stronger ability to migrate and invade, as well as display higher IKKβ/NF-κB activity compared to their parental partners. Importantly, we found that knockdown of IKKβ, but not NF-κB, dramatically impaired cell migration and invasion in these cells. Consistent with this, the IKKβ inhibitor, CmpdA, also inhibited cell migration and invasion. Previous studies have already shown that N-Cadherin, an epithelial-mesenchymal transition (EMT) marker, and IL-6, a pro-inflammatory cytokine, play important roles in regulation of HNSCC migration, invasion, and metastasis. We found that cisplatin-resistant HNSCC expressed higher levels of N-Cadherin and IL-6, which were significantly inhibited by CmpdA. More importantly, we showed that CmpdA treatment dramatically abated cisplatin-resistant HNSCC cell metastasis to lungs in a mouse model. Our data demonstrated the crucial role of IKKβ in control of migration, invasion, and metastasis, and implicated that targeting IKKβ may be a potential therapy for cisplatin-resistant metastatic HNSCC.

Keywords: Cisplatin resistance; HNSCC; Head and neck squamous cell carcinoma; IKKβ; IKKβ inhibitor; Invasion; Metastasis; Migration; NF-κB.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Movement / genetics
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Drug Resistance, Neoplasm / genetics
  • Epithelial-Mesenchymal Transition / drug effects
  • Epithelial-Mesenchymal Transition / genetics
  • Gene Knockdown Techniques
  • Head and Neck Neoplasms / drug therapy*
  • Head and Neck Neoplasms / genetics
  • Head and Neck Neoplasms / pathology
  • Humans
  • I-kappa B Kinase / antagonists & inhibitors*
  • I-kappa B Kinase / genetics
  • I-kappa B Kinase / metabolism
  • Lung Neoplasms / genetics
  • Lung Neoplasms / prevention & control*
  • Lung Neoplasms / secondary
  • Mice
  • NF-kappa B / metabolism*
  • Neoplasm Invasiveness / genetics
  • Neoplasm Invasiveness / prevention & control
  • Neoplasm Metastasis / genetics
  • Neoplasm Metastasis / prevention & control
  • Oxazines / pharmacology
  • Oxazines / therapeutic use*
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • RNA, Small Interfering / metabolism
  • Signal Transduction / drug effects
  • Squamous Cell Carcinoma of Head and Neck / drug therapy*
  • Squamous Cell Carcinoma of Head and Neck / genetics
  • Squamous Cell Carcinoma of Head and Neck / secondary
  • Xenograft Model Antitumor Assays

Substances

  • Bay 65-1942
  • NF-kappa B
  • Oxazines
  • Pyridines
  • RNA, Small Interfering
  • I-kappa B Kinase
  • IKBKB protein, human
  • Cisplatin